Abstract
Kalincik T, Jokubaitis V, Spelman T, et al. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. Mult Scler. Epub ahead of print 31 August 2017. DOI: 10.1177/1352458517728812
On page 5 of this article there was a typographical error in the initial Online First version. The fourth line of the first paragraph that read ‘The probability of disability accumulation was similar in the two matched cohorts (HR: 0.41 (95% CI: 0.87–1.47), p = 0.37)’ should have read ‘The probability of disability accumulation was similar in the two matched cohorts (HR: 0.61 (95% CI: 0.20-1.82), p=0.37)’. The incorrect values were also repeated in Figure 2b.
Both the sentence and the figure have now been corrected online.
The authors apologise for any inconvenience.
Get full access to this article
View all access options for this article.